A Different Approach to Health Plans with HealthWallet’s Ryan Coplon

Healthcare plans are easy when one doesn’t need to use them, but navigating a plan to receive needed care can prove challenging. Ryan Coplon, Co-Founder & President of HealthWallet, believes there is a better way to make order out of the healthcare chaos, and that’s through HealthWallet’s smartphone app. He spoke with Kevin Stevenson about HealthWallet’s unique approach to giving people the healthcare access they desire when they need it.

Coplon’s background comes from the employee benefits and health plan architecture, and that experience shaped his ideas on ways in which a better health plan program could benefit those in need of options. “We realized the more progressive we got with our plan design and infrastructure, the more confused our plan members got,” Coplon said. “So, I saw an opportunity to partner with my co-founder now, in collaboration with the health plan that we managed.” After a year of development, they created an easy platform to drive utilization at the plan level. Once their idea solved these issues, Coplon and his partner recognized the potential to mainstream this idea.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…